Matching articles for "1665c"
Issue 1665 · December 12, 2022 Free
An EUA for Anakinra (Kineret) for COVID-19 (online only)

The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19…

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e203-4
The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19 pneumonia who require low- or high-flow supplemental oxygen, are at risk of progressing to severe respiratory failure, and are likely to have elevated plasma levels of soluble urokinase plasminogen activator receptor (suPAR). Anakinra has been available in the US for years; it is FDA-approved for multiple indications, including rheumatoid arthritis. Assays for suPAR are not commercially available in the US.